Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-Uninfected female subjects

Journal of Clinical Pharmacology

Volumn 54, Issue 11, 2014, Pages 1290-1298

  German, P ^a   Moorehead, L ^a   Pang, Phillip ^a   Vimal, M ^a   Mathias, A ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

ledipasvir; oral contraceptives; pharmacokinetics; sofosbuvir

Indexed keywords

ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; DRUG ADMINISTRATION; DRUG METABOLITE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTIMATE; FLUORENE DERIVATIVE; FOLLITROPIN; GS 331007; GS 566500; LEDIPASVIR; LUTEINIZING HORMONE; NORGESTIMATE, ETHINYL ESTRADIOL DRUG COMBINATION; NORGESTREL; ORAL CONTRACEPTIVE AGENT; PHARMACOKINETICS; PROGESTERONE; SOFOSBUVIR; UNCLASSIFIED DRUG; URIDINE PHOSPHATE;

ABNORMAL LABORATORY RESULT; ADULT; ALTERNATIVE HYPOTHESIS; ANALOGS AND DERIVATIVES; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INTERACTION; DRUG WITHDRAWAL; ELIMINATION RATE CONSTANT; FEMALE; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; HALF LIFE TIME; HEPACIVIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSOMNIA; LIMIT OF QUANTITATION; LUTEINIZING HORMONE BLOOD LEVEL; MAXIMUM PLASMA CONCENTRATION; MENSTRUAL CYCLE; MENSTRUATION DISORDER; MORNING DOSAGE; OPEN STUDY; ORAL CONTRACEPTION; OVULATION; PHASE 1 CLINICAL TRIAL; STEADY STATE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION AND DOSAGE; ADULT; ANALOGS AND DERIVATIVES; ANTIVIRAL AGENTS; AREA UNDER CURVE; BENZIMIDAZOLES; CONTRACEPTIVES, ORAL, COMBINED; DRUG INTERACTIONS; ETHINYL ESTRADIOL; FEMALE; FLUORENES; HALF-LIFE; HEPACIVIRUS; HUMANS; NORGESTREL; PHARMACOKINETICS; URIDINE MONOPHOSPHATE;

EID: 85027949450     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.346     Document Type: Article

References (26)

1. SOVALDI® (sofosbuvir) tablets, for oral use. US Prescribing Information. Gilead Sciences, Inc. Foster City, CA. December 2013.
2. REBETOL® (ribavirin, USP) Capsules and Oral Solution. US Prescribing Information. Schering Corporation, Kenilworth, NJ. Revised November 2013.
3. Hammond GL, Abrams LS, Creasy GW, Natarajan J, Allen JG, Siiteri PK,. Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. Contraception. 2003; 67: 93-99.
4. ORTHO TRI-CYCLEN® Lo Tablets (norgestimate/ethinyl estradiol). US Prescribing Information. Janssen Ortho, LLC. Manati, Puerto Rico. Revised August 2012.
5. Kearney BP, Mathias A,. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Pharmacotherapy. 2009; 29: 924-929.
6. Zhang H, Cui D, Wang B, et al. Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet. 2007; 46: 133-157.
7. Kirby B, Mathias A, Yang C, et al. Metabolism and Excretion of Ledipasvir (GS-5885) in Humans. In: International Workshop on Clinical Pharmacology of Hepatitis Therapy [Poster O-22]. 2013 June 26-27, Cambridge, MA; 2013.
8. Kirby B, Mathias A, Rossi SJ, Moyer C, Shen G, Kearney BP,. No Clinically Significant Pharmacokinetic Drug Interactions between Sofosbuvir (GS-7977) and HIV Antiretrovirals Atripla®, Rilpivirine, Darunavir/ritonavir, or Raltegravir in Healthy Volunteer [Abstract 1877]. In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 2012 November 9-13; Boston, MA. Hepatology AASLD Abstracts 2012;56:1067A.
9. Mathias A, Cornpropst M, Clemons D, Denning J, Symonds WT,. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers [Abstract 1869]. Hepatol AASLD Abst. 2012; 56: 1063-4A.
10. German P, Mathias A, Pang PS, et al. Lack of Clinically Signifi cant Pharmacokinetic Drug-Drug Interaction Between Sofosbuvir (GS-7977) and GS-5885 or GS-9669 in Healthy Volunteers [Poster 1888]. In: 63rd Annual Meeting of the American Association for the Study of Liver Diseases, 2012 November 9-13, 2012; Boston, Massachusetts, United States: Gilead Sciences, Inc.; 2012.
11. Division of AIDS (DAIDS) Table of Grading Severity of Adult and Pediatric Adverse Events. 2004. 2004. (Accessed April 29, 2010, at http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegradingtable.pdf).
12. Andrews E, Damle BD, Fang A, et al. Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. Br J Clin Pharmacol. 2008; 65: 531-539.
13. Zhang J, Chung E, Yones C,. et al. The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antivir Ther. 2011; 16: 157-164.
14. Simonson SG, Martin PD, Warwick MJ, Mitchell PD, Schneck DW,. The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive. Br J Clin Pharmacol. 2004; 57: 279-286.
15. Vogler MA, Patterson K, Kamemoto L,. et al. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. J Acquir Immune Defic Syndr. 2010; 55: 473-482.
16. INTELENCE® (etravirine) tablets for oral use. US Prescribing Information. Janssen Pharmaceuticals, Inc. 2008 Titusville NJ. Revised February 2013.
17. Weber A, Jager R, Borner A,. et al. Can grapefruit juice influence ethinylestradiol bioavailability. Contraception. 1996; 53: 41-47.
18. Kirby B, Gordi T, Symonds WT, Kearney BP, Mathias A,. Population Pharmacokinetics of Sofosbuvir and Its Major Metabolite (GS-331007) in Healthy and HCV-Infected Adult Subjects [Poster 1106]. In: The Liver Meeting® 2013 The 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 2013 November 1-5, Washington D.C.; 2013.
19. Kirby B, Li H, Kearney BP, Mathias A,. Population Pharmacokinetics of Ledipasvir (GS-5885) in Healthy and HCV-Infected Adult Subjects [Poster 33]. In: International Workshop on Clinical Pharmacology of HCV and HIV Therapy, 2014 May 19-21, Washington D.C.; 2014.
20. Quest Diagnostics FSH and LH Reference Ranges. http://www.questdiagnostics.com/testcenter/BUOrderInfo.action?tc=7137&labCode=SEA. Accessed June 13, 2014.
21. Quest Diagnostics Liquid Chromatography Tandem Mass Spectrometry Progesterone Test Reference Ranges. http://www.questdiagnostics.com/testcenter/TestDetail.action?ntc=17183. Accessed June 13, 2014.
22. German P, Mathias A, Yang C, et al. Pharmacokinetics of Ledipasvir, an HCV-Specific NS5A Inhibitor, in HCV-Uninfected Subjects with Moderate or Severe Hepatic Impairment [Poster 467]. In: The Liver Meeting® 2013 The 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 2013 November 1-5, Washington, D.C.; 2013.
23. Afdhal N, Zeuzem S, Kwo P,. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. New Engl J Med. 2014.
24. Kowdley KV, Gordon SC, Reddy KR,. et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014.
25. Afdhal N, Reddy KR, Nelson DR,. et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. New Engl J Med. 2014; 370: 1483-1493.
26. Barditch-Crovo P, Trapnell CB, Ette E,. et al. The effects of rifampin and rifabutin on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive. Clin Pharmacol Ther. 1999; 65: 428-438.